What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Gene
His primary areas of investigation include Prostate cancer, Internal medicine, Prostate-specific antigen, Prostate and Cancer.
Hans Lilja has researched Prostate cancer in several fields, including Urology, Gynecology, Mass screening and Pathology.
His research in Internal medicine intersects with topics in Endocrinology and Oncology.
His Prostate-specific antigen research is multidisciplinary, incorporating elements of Kallikrein, Biopsy, Prostatectomy and Antigen.
Hans Lilja has included themes like Immunohistochemistry, Cancer research, Adenoma, Zymogen and Hyperplasia in his Prostate study.
In his research, Biomarker is intimately related to Biomarker discovery, which falls under the overarching field of Cancer.
His most cited work include:
- Screening and Prostate-Cancer Mortality in a Randomized European Study (3160 citations)
- Prostate-Cancer Mortality at 11 Years of Follow-up (964 citations)
- Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up (887 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Prostate cancer, Internal medicine, Prostate-specific antigen, Oncology and Prostate.
His Prostate cancer study results in a more complete grasp of Cancer.
His work carried out in the field of Internal medicine brings together such families of science as Kallikrein and Endocrinology.
Hans Lilja combines subjects such as Antigen, Mass screening, Prostate biopsy, Biopsy and Molecular biology with his study of Prostate-specific antigen.
His Oncology research incorporates themes from Randomized controlled trial, Proportional hazards model, Disease, Biomarker and Overdiagnosis.
His Prostate study combines topics from a wide range of disciplines, such as Immunoassay and Hyperplasia.
He most often published in these fields:
- Prostate cancer (87.52%)
- Internal medicine (62.27%)
- Prostate-specific antigen (63.80%)
What were the highlights of his more recent work (between 2015-2021)?
- Prostate cancer (87.52%)
- Internal medicine (62.27%)
- Oncology (43.13%)
In recent papers he was focusing on the following fields of study:
Hans Lilja mostly deals with Prostate cancer, Internal medicine, Oncology, Prostate-specific antigen and Prostate.
Prostate cancer is the subject of his research, which falls under Cancer.
The study of Internal medicine is intertwined with the study of Gynecology in a number of ways.
His studies deal with areas such as Early detection, Kallikrein, Proportional hazards model, Disease and Biomarker as well as Oncology.
His Prostate-specific antigen study incorporates themes from Genome-wide association study, Single-nucleotide polymorphism, Incidence, Cohort study and Mass screening.
His research combines Overdiagnosis and Prostate.
Between 2015 and 2021, his most popular works were:
- A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer (95 citations)
- A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort (56 citations)
- A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort (56 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Cancer
- Internal medicine
His scientific interests lie mostly in Prostate cancer, Internal medicine, Prostate-specific antigen, Oncology and Prostate.
His studies in Prostate cancer integrate themes in fields like Cancer research, Genome-wide association study, Antigen and Medical genetics.
His Prostate-specific antigen study combines topics in areas such as Rate ratio, Incidence, Gynecology and Mass screening.
His biological study spans a wide range of topics, including Biopsy and Cohort.
The concepts of his Biopsy study are interwoven with issues in Kallikrein and Urology.
His Prostate biopsy research includes themes of Overdiagnosis and PCA3.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
